Category Archives: Corporate News

Bioserve India Launches Advanced Stem Cell Products in India

Hyderabad, India – 22nd July 2024 – Bioserve India is excited to announce the launch of its advanced stem cell products in India. These new products from REPROCELL aims to support innovation in scientific research and drug development, supporting advancements in regenerative medicine and therapeutic discovery in Indian Market. The stem cell market is a rapidly growing industry that encompasses a wide range of services and products. Within the stem cell market, numerous industries are engaged in critical activities such as research and development manufacturing, and distribution of stem cell therapy products.

REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells

REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for generation of Human Induced Pluripotent Cells (hiPSC) and Human Mesenchymal Stem Cells (hMSC) for human therapeutic applications.

Bioserve Biotechnologies and RISVI Trading Announce New Distributorship Agreement in Qatar

Hyderabad, India and Doha, Qatar – May 6, 2024 – Bioserve Biotechnologies (India) Private Limited, a leader in molecular biology products, is excited to announce a new distributorship agreement with RISVI Trading W.L.L., a renowned trading company based in Doha, Qatar. This strategic partnership will enable Bioserve to expand its distribution network for molecular biology products, including DNA oligonucleotide synthesis in Qatar.

Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market.

Hyderabad, India, 27th September 2023: Bioserve Biotechnologies (India) Private Limited, a leader in molecular biology products, is teaming up with BioMavericks Ltd., a UK-based company. This partnership will allow Bioserve to extend its molecular biology product distribution, including DNA oligonucleotide synthesis across the United Kingdom.

REPROCELL invests in Histocell, S.L. a Spain-based CDMO

Yokohama Japan, 23 November 2022: REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings.